Naslov
Maximising benefits and minimizing harms from drugs imatinib determination in human serum by high-performance liquid chromatography

Autori
Granić, Paula ; Sertić, Dubravka ; Lovrić, Mila ; Lalić, Zdenka ; Božina, Nada ; Labar, Boris ; Sertić, Jadranka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Basic & Clinical Pharmacology & Toxicology. Supplement 1. / Brøsen, Kim. - Kopenhagen : Nordic Pharmacological Society, 2010, 309-309

Skup
16th World Congress of Basic and Clinical Pharmacology

Mjesto i datum
Kopenhagen, Danska, 17.07.2010. - 23.07.2010

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
imatinib; human serum; HPLC

Sažetak
Introduction: Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It is used in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. Materials and Methods: The aim of this study was to develop and validate sensitive and specific high-perfomance liquid chromatography (HPLC) method for the determination of imatinib in serum/plasma. Imatinib was extracted from serum with methanol. Clozapine was used as an internal standard. The sample was fractionated on a column MN EC Nucleosil 100-5-C-18 EC 250 x 4.6 mm with a mobile system consisting of ammonium acetate buffer, methanol and acetonitrile (40:40:20). The flow rate was 0.75 ml min-1. Quantitation was performed by measurement of UV detector at the wavelength of 265 nm. Results: Calibration curve was linear in the range of 40 - 5000 ng/ml, limit of detection (LOD) was 13.1 ng/ml and limit of quantitation (LOQ) was 38.6 ng/m. Recovery ranged from 94.1% to 105.7%. Repeatability expressed as a coefficient of variation was 4.90% and 1.95% for 75 and 1500 ng/ml, respectively, and the coefficient of variation for intermediate precision was <10.0%. Stability of the analyte during several freeze/thaw cycles and long-term stability (during 21 days) was good. Conclusion: The method proved to be simple, useful, enough sensitive and specific for routine monitoring of imatinib concentrations in patients with chronic myelogenous leukemia.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA